Ceftriaxone Sodium

CHEMBL6067656 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

598.6 g/mol

LogP

—

Phase

4

The sodium salt preparation of ceftriaxone is the standard formulation used in clinical practice for intravenous or intramuscular injection. It shares all the pharmacological properties and indications of the parent compound, including once-daily dosing convenience. Special caution is required in neonates due to the risk of biliary sludge and interactions with calcium-containing infusion fluids.

Molekularmasse

598,6000 g/mol

TPSA

280,00 Å²

Therapeutische Bereiche

Benign Prostatic Hyperplasia Cardiovascular Disease Chronic Obstructive Pulmonary Disease Parkinson's Disease Schizophrenia Bipolar Disorder Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Stroke Hypertension HIV/AIDS Tuberculosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(CSc3nc(=O)c([O-])nn3C)CS[C@H]12)c1csc(N)n1.CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(CSc3nc(=O)c([O-])nn3C)CS[C@H]12)c1csc(N)n1.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+]

InChI

InChI=1S/2C18H18N8O7S3.4Na.7H2O/c2*1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;;;;;;;;;;/h2*5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32);;;;;7*1H2/q;;4*+1;;;;;;;/p-4/b2*24-8-;;;;;;;;;;;/t2*9-,15-;;;;;;;;;;;/m11.........../s1

Molecular Formula

C18H16N8Na2O7S3

HBD / HBA

2 / 14

Rotierbare Bindungen

8

Schwere Atome

38

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The sodium salt preparation of ceftriaxone is the standard formulation used in clinical practice for intravenous or intramuscular injection. It shares all the pharmacological properties and indications of the parent compound, including once-daily dosing convenience. Special caution is required in neonates due to the risk of biliary sludge and interactions with calcium-containing infusion fluids.

Yes, Ceftriaxone Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6067656. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 23715082. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Ceftriaxone Sodium auf PillFYI

Struktur

Schnelldaten

Formel: C18H16N8Na2O7S3
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.